tarsus pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. its lead product candidate is tp-03, a novel therapeutic that is in phase iib/iii for the treatment of blepharitis caused by the infestation of demodex mites, as well as to treat meibomian gland disease. the company is also developing tp-04 for the treatment of rosacea; and tp-05 for lyme prophylaxis and community malaria reduction. tarsus pharmaceuticals, inc. was founded in 2016 and is headquartered in irvine, california.
Company profile
Ticker
TARS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
814717861
TARS stock data
Latest filings (excl ownership)
8-K
Other Events
5 Mar 24
8-K
Tarsus Announces Proposed $100.0 Million Public Offering
1 Mar 24
424B5
Prospectus supplement for primary offering
1 Mar 24
424B5
Prospectus supplement for primary offering
29 Feb 24
S-3ASR
Automatic shelf registration
29 Feb 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
26 Feb 24
8-K
Departure of Directors or Certain Officers
18 Jan 24
8-K
Leading the Way in Category Creation J A N U A R Y 2 0 2 4 Sulma, an XDEMVY® Patient
8 Jan 24
Transcripts
Latest ownership filings
144
Notice of proposed sale of securities
11 Apr 24
144
Notice of proposed sale of securities
28 Mar 24
4
Aziz Mottiwala
19 Mar 24
4
Bryan Wahl
19 Mar 24
4
Bobak R. Azamian
19 Mar 24
4
Dianne C. Whitfield
19 Mar 24
4
Seshadri Neervannan
19 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 226.67 mm | 226.67 mm | 226.67 mm | 226.67 mm | 226.67 mm | 226.67 mm |
Cash burn (monthly) | (no burn) | (no burn) | 13.65 mm | 9.48 mm | 10.79 mm | 7.42 mm |
Cash used (since last report) | n/a | n/a | 90.78 mm | 63.07 mm | 71.76 mm | 49.36 mm |
Cash remaining | n/a | n/a | 135.90 mm | 163.60 mm | 154.91 mm | 177.31 mm |
Runway (months of cash) | n/a | n/a | 10.0 | 17.3 | 14.4 | 23.9 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 113 |
Opened positions | 25 |
Closed positions | 11 |
Increased positions | 49 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 520.09 bn |
Total shares | 41.39 mm |
Total puts | 16.40 k |
Total calls | 31.00 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
RTW Investments | 2.88 mm | $51.19 bn |
Cormorant Asset Management | 2.62 mm | $46.58 bn |
Vivo Capital | 2.26 mm | $40.20 bn |
Vivo Capital IX | 2.26 mm | $0.00 |
BLK Blackrock | 2.21 mm | $39.28 bn |
Tang Capital Management | 2.14 mm | $38.04 bn |
Tang Capital Partners | 2.00 mm | $0.00 |
Limited Partnership VIII Horowitz | 1.99 mm | $42.15 mm |
Cowen And | 1.80 mm | $31.93 bn |
Frazier Life Sciences Management | 1.79 mm | $31.76 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Mar 24 | Aziz Mottiwala | Common Stock | Sell | Dispose S | No | No | 30.6 | 4,766 | 145.84 k | 54,075 |
18 Mar 24 | Bryan Wahl | Common Stock | Sell | Dispose S | No | No | 30.6 | 4,436 | 135.74 k | 40,951 |
18 Mar 24 | Dianne C. Whitfield | Common Stock | Sell | Dispose S | No | No | 30.6 | 4,314 | 132.01 k | 34,181 |
18 Mar 24 | Bobak R. Azamian | Common Stock | Sell | Dispose S | No | No | 30.6 | 10,415 | 318.70 k | 26,456 |
18 Mar 24 | Seshadri Neervannan | Common Stock | Sell | Dispose S | No | No | 30.6 | 4,879 | 149.30 k | 64,767 |
15 Mar 24 | Aziz Mottiwala | Common Stock | Option exercise | Acquire M | No | No | 0 | 12,938 | 0.00 | 58,841 |
15 Mar 24 | Aziz Mottiwala | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 8,148 | 0.00 | 24,444 |
15 Mar 24 | Aziz Mottiwala | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 4,790 | 0.00 | 9,580 |
15 Mar 24 | Bryan Wahl | Common Stock | Option exercise | Acquire M | No | No | 0 | 12,038 | 0.00 | 45,387 |
15 Mar 24 | Bryan Wahl | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 7,248 | 0.00 | 21,745 |
News
Tarsus Prices $100M Public Offering Of 2,812,500 Common Shares At $32/Share
1 Mar 24
Tarsus Pharmaceuticals Reveals Proposed $100M Public Offering
29 Feb 24
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
29 Feb 24
Goldman Sachs Maintains Neutral on Tarsus Pharmaceuticals, Raises Price Target to $30
29 Feb 24
HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $57
28 Feb 24
Press releases
Tarsus Announces Pricing of $100.0 Million Public Offering
1 Mar 24
Tarsus Announces Proposed $100.0 Million Public Offering
29 Feb 24
Thinking about buying stock in Summit Materials, Informatica, Unicycive Therapeutics, Tarsus Pharmaceuticals, or Zion Oil and Gas?
29 Feb 24
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
20 Feb 24
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
31 Jan 24